Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | ADA | P00813 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 2/20 | 0.30 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5017258 | 0.88 | CA12 (0.39) | HTR6CA12CA1CA9ADRB2 | |
| SCHEMBL5016711 | 0.83 | CA12 (0.35) | CA12CA1CA9PREP | |
| SCHEMBL5015480 | 0.79 | CA12 (0.39) | CA12CA1CA9PREP | |
| SCHEMBL5015519 | 0.79 | CA12 (0.39) | CA12CA1CA9PREP | |
| SCHEMBL7257408 | 0.72 | CA12 (0.40) | CA12CA1CA9ADRB2PREP | |
| SCHEMBL7258416 | 0.71 | TYR (0.40) | CA12CA1CA9PREP | |
| SCHEMBL5015425 | 0.71 | CA12 (0.39) | CA12CA1CA9PREP | |
| SCHEMBL5015465 | 0.71 | CA12 (0.39) | CA12CA1CA9PREP | |
| SCHEMBL3406627 | 0.70 | PLA2G4A (0.41) | HTR6ADRB2 | |
| SCHEMBL8050536 | 0.69 | MTNR1A (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644368-B1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-7235572-B2 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1644368-A1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005005423-A1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-20 | — | — | WO | disclosed |
| US-20050004187-A1 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004187-A1 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | HTR6 175/4885CA12 4869/4885CA1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.